It depends on the standard you follow. As of September 2026, GE HealthCare Technologies Inc. (GEHC) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes S&P Global, Dow Jones, MSCI and FTSE, and fails AAOIFI.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 30.9% / 30% · (Cash+Inv) / Mkt Cap (36m) 10.0% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 30.9% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 8.84% / 33% · Receivables / Mkt Cap (36m) 12.2% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 30.9% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 8.84% / 33.33% · Receivables / Mkt Cap (24m) 12.2% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 27.0% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 7.86% / 33.33% · Receivables / Avg Assets (4Q) 11.0% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| FTSE | Debt / Total Assets 26.0% / 33.33% · (Cash+ST Inv) / Total Assets 7.44% / 33.33% · (Cash+Recv) / Total Assets 17.7% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
It depends on the standard you follow. As of September 2026, GE HealthCare Technologies Inc. (GEHC) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes S&P Global, Dow Jones, MSCI and FTSE, and fails AAOIFI.
No. GE HealthCare Technologies Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m).
GE HealthCare Technologies Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
GE HealthCare Technologies Inc. (NASDAQ: GEHC) is a Healthcare company (Medical - Devices) with a market capitalization of $37.2B. The Maz Rating grades it against the other companies in its sector.
GE HealthCare Technologies Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $82.27, GE HealthCare Technologies Inc. trades at 17.5x trailing earnings, 1.7x sales and 3.2x book value, with an EV/EBITDA of 11.8. Over the last twelve months it generated about $21.5B of revenue and $2.1B of net income. It runs a gross margin of 39.9%, an operating margin of 13.3% and a net margin of 10.0%. It shows return on equity of 19.8%, return on invested capital of 7.8% and a free cash flow yield of 5.0%. On the balance sheet: a debt-to-equity ratio of 0.90 and a current ratio of 1.30. Over the past 52 weeks the share price ranged from $58.75 to $89.77, with a beta of 0.77.
GE HealthCare Technologies Inc. pays a dividend yielding 0.17%, with 3% of earnings paid out. Its Maz Dividend Score is 3.57 out of 5, ranked against the other dividend payers in its sector (Safety 4.83, Growth 2.83, Yield 1.57, Consistency 1.71).
20 Wall Street analyst ratings cover the stock: 13 Buy and 7 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.